Veradermics Prices $384M Stock Offering at $100 After Hair Loss Drug Hits Phase 2/3 Goals
NEW YORK, May 1 —
Veradermics, Incorporated (MANE) priced an upsized 3.84 million-share offering at $100 a share, hours after its oral hair loss drug VDPHL01 cleared its Phase 2/3 readout.
- 3.84M shares priced at $100, gross proceeds of roughly $384M before fees
- Stock trades at $99 with a -31.1x forward P/E, the negative multiple flagging that the Street still models cash burn through commercial launch
- Concurrent private placement adds a $300k warrant PIPE on top of the public deal
What Actually Happened
Veradermics did the textbook biotech double-tap: drop a positive trial result, then sell stock into the rally. VDPHL01 hit its hair growth endpoints in a Phase 2/3 study for male pattern hair loss, and management used the window to upsize the raise and lock in $384M plus the warrant PIPE. The offering pricing right at $100 versus a $99 last print tells you the book was strong enough to clear at spot, with no fire-sale discount. For a pre-revenue dermatology company, that is the cleanest possible execution.
The Catch
The clinical de-risking is real. The dilution is also real. A 3.84M-share issuance at $100 is the kind of slug that resets the float and the per-share math overnight, and the forward P/E of -31.1x is a reminder that earnings are a long way off. Hair loss is also a category where Propecia (finasteride) has been generic and cheap for two decades, so VDPHL01's commercial case rests on showing a real efficacy or safety edge, not just regulatory approval. The next 10-Q will give the first clean look at the post-offering share count and runway.
Bottom Line
This is more interesting after the news, not less. Veradermics now has data, cash, and a clear path to an NDA filing, which is a rare trifecta for a small-cap dermatology name. Growth investors with stomach for binary outcomes get the cleaner setup here. Value investors should keep walking. The number to watch is the post-deal share count in the next 10-Q, because that is what turns $384M of headline cash into a real per-share runway figure.
Basis Report has not yet published a full report on MANE. Generate one at /stock/mane to see the full financial breakdown and runway model.
Basis Report does not hold positions in securities discussed. This is not investment advice.